Literature DB >> 2537153

Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.

M van Lohuizen1, S Verbeek, P Krimpenfort, J Domen, C Saris, T Radaszkiewicz, A Berns.   

Abstract

Transgenic mice bearing the pim-1 gene supplemented with an upstream immunoglobulin enhancer and a downstream murine leukemia virus long terminal repeat express pim-1 mRNA at high levels in both B and T cells. Between 5% and 10% of the pim-1 transgenic mice develop clonal T cell lymphomas before 7 months of age, whereas none of the age-matched control mice do, providing direct evidence for the oncogenic potential of pim-1. Histological examination and FACS analysis revealed no abnormalities in hematopoietic tissues of disease-free pim-1 transgenic mice. When newborn pim-1 transgenic mice are infected with MuLV, T cell lymphomas develop much faster (latency 7-8 weeks) than in nontransgenic mice (latency 22 weeks). In all these T cell lymphomas either c-myc or N-myc was activated by proviral insertion, suggesting strong cooperation between pim-1 and myc in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537153     DOI: 10.1016/0092-8674(89)90589-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  155 in total

1.  Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP.

Authors:  U Konietzko; G Kauselmann; J Scafidi; U Staubli; H Mikkers; A Berns; M Schweizer; R Waltereit; D Kuhl
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  An Integrated Genetic-Genomic Approach for the Identification of Novel Cancer Loci in Mice Sensitized to c-Myc-Induced Apoptosis.

Authors:  Susan M Mendrysa; Keiko Akagi; Jean Roayaei; Wen-Hui Lien; Neal G Copeland; Nancy A Jenkins; Robert N Eisenman
Journal:  Genes Cancer       Date:  2010-05

3.  Inhibition of Pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation.

Authors:  Yoo Seob Shin; Katsuyuki Takeda; Yoshiki Shiraishi; Yi Jia; Meiqin Wang; Leila Jackson; A Dale Wright; Laura Carter; John Robinson; Erik Hicken; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2011-11-10       Impact factor: 6.914

4.  Nucleotide sequence of bup, an upstream gene in the bmi-1 proviral insertion locus.

Authors:  Y Haupt; G Barri; J M Adams
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

Review 5.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

6.  p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Authors:  Marina Zemskova; Michael B Lilly; Ying-Wei Lin; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

Review 7.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

8.  Insertional activation of N-myc by endogenous Moloney-like murine retrovirus sequences in macrophage cell lines derived from myeloma cell line-macrophage hybrids.

Authors:  M Setoguchi; Y Higuchi; S Yoshida; N Nasu; Y Miyazaki; S Akizuki; S Yamamoto
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

9.  Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement.

Authors:  C Tsatsanis; R Fulton; K Nishigaki; H Tsujimoto; L Levy; A Terry; D Spandidos; D Onions; J C Neil
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Evi-5, a common site of retroviral integration in AKXD T-cell lymphomas, maps near Gfi-1 on mouse chromosome 5.

Authors:  X Liao; A M Buchberg; N A Jenkins; N G Copeland
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.